



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/730680		
		Filing Date	December 8, 2003		
		First Named Inventor	Nicole Barvian, et al.		
		Art Unit	Not Yet Known 1624		
Examiner Name	Not Yet Known COLEMAN				
Sheet	2	of	4	Attorney Docket Number	PC 50508

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		ANDREI, et al., Somatic Mutation and Homozygous Deletion of PTEN/MMAC1 Gene 10q23 in Renal Cell Carcinoma, Anticancer Research, 1999, pp 3841-3846, Vol 19	
BC		BORLANDO, et al., Increase phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo, FASEB J., May 2000, pp. 895-903, Vol 14	
BC		BRASS, et al., DNA Amplification on Chromosome 3q26.1-q26.3 in Squamous Cell Carcinoma of the Lung Detected by Reverse Chromosome Painting, Eur. J. Cancer, 1996, pp 1205-1208, Vol 32A(7), Great Britain	
BC		FORGACS, et al., Mutation analysis of the PTEN/MMAC1 gene in lung cancer, Oncogene, 1998, pp 1557-1565, Vol 17	
BC		HIRSCH, et al., Central Role for G Protein-Coupled Phosphoinositide 3-Kinase in Inflammation, Science, February 2000, pp 1049-1053, Vol 287, USA	
BC		HIRSCH, et al., Resistance to thromboembolism in PI3Ky-deficient mice, FASEB Journal, July 2001, pp. 2019-2021, USA	
BC		HU, et al., Inhibition of Phosphatidylinositol, 3'-Kinase Increases Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models, Cancer Res., February 2002, pp. 1087-1092, Vol 62	
BC		JIMENEZ, et al., Identification and characterization of new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase, EMBO Journal, 1998, pp 743-753, Vol 17(3), USA	
BC		KATSO, et al., Cellular Function of phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer, Annu. Rev. Cell Dev. Biol. 2001, pp 615-675, Vol 17, USA	
BC		KOTELEVETS, et al., Inhibition by Platelet-activating Factor of Src-and Hepatocyte Growth Factor-dependent Invasiveness of Intestinal and Kidney Epithelial Cells, J. Biol. Chem., June 1998, pp 14138-14145, Vol 273(23), USA	

Examiner Signature	Brenda Coleman	Date Considered	May 24, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/743,852		
		Filing Date	December 22, 2003		
		First Named Inventor	Rocco Dean Gogliotti, et al		
		Art Unit	Not Yet Known 1624		
		Examiner Name	Not Yet Known COLEMAN		
Sheet	3	of	4	Attorney Docket Number	PC 25547A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		KRCHAK, et al., A solid phase traceless synthesis of quinoxalinones, Tetrahedron Letters, 2000, pp 2835-2838, USA	
BC		LEE, et al., Solid-phase combinatorial synthesis of 5-arylalkylidene rhodanine, Tetrahedron Letters, 2000, pp 5729-5732, USA	
BC		LEE, et al., The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia, Leukemia, 2002, pp 486-507, Vol 16, USA	
BC		LEOPOLDT, et al., GBY Stimulates Phosphoinositide 3-Kinase-y by Direct Interaction with Two Domains of the Catalytic p110 Subunit, December 1997, pp 7024-7029, Vol 273(12), USA	
BC		MA, et al., PIK3CA as an oncogene in cervical cancer, Oncogene, 2000, pp 2739-2744, Vol 19,	
BC		NAKANISHI, et al., Novel Functions of Phosphatidylinositol 3-Kinase in Terminally Differentiated Cells, Cellular Signalling, 1995, pp 545-557, Vol 6, Great Britain	
BC		PHILP, et al., The Phosphatidylinositol 3'-kinase p85a Gene Is an Oncogene in Human Ovarian and Colon Tumors, Cancer Research, October 2001, pp 7426-7429, Vol 61, USA	
BC		SHAYESTEH, et al., PIK3CA is implicated as an oncogene in ovarian cancer, Nature Genetics, January 1999, pp. 99-102, Vol 21	
BC		SUSA, et al., Platelet-derived Growth Factor Activates Membrane-associated Phosphatidylinositol 3-Kinase and Mediates Its Translocation from the Cytosol, November 1992. Pp 22951-22956, Vol 267(32), USA	
BC		VANHAESEBROECK, et al., p110d, a novel phosphoinositide 3-kinase in leukocytes, Proc. Natl. Acad. Sci., April 1997, pp. 4330-4335, Vol. 94, USA	

Examiner Signature	Brenda Coleman	Date Considered	May 24, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/743,852
				Filing Date	December 22, 2003
				First Named Inventor	Rocco Dean Gogliotti, et al
				Art Unit	Not Yet Known 1624
				Examiner Name	Not Yet Known COLEMAN
Sheet	4	of	4	Attorney Docket Number	PC 25547A

[illegible]

Examiner Signature	Brenda Coleman	Date Considered	May 24 2006
-----------------------	----------------	--------------------	-------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1** Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/743,852
Filing Date	December 22, 2003
First Named Inventor	Rocco Dean Gogliotti, et al
Art Unit	Not Yet Known 1624
Examiner Name	Not Yet Known COLEMAN
Attorney Docket Number	PC25547A

Sheet	1	of	1
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>d</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
BC		WO 04/007491	01-22-2004	Applied Research		
BC	03-12-2002	WO 00/76987	12-21-2000	Warner-Lambert		
BC		WO 00/76988	12-21-2000	Warner-Lambert		

Examiner Signature	Brenda Coleman	Date Considered	May 24 2006
-----------------------	----------------	--------------------	-------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/743,852
		Filing Date	December 22, 2003
		First Named Inventor	Rocco Dean Gogliotti, et al.
		Art Unit	<del>Not Yet Known</del> 1624
		Examiner Name	<del>Not Yet Known</del> COLEMAN
Sheet 1 of 2	Attorney Docket Number	PC 25547A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		Chemical Abstract AN: 2003:1957877 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2003:1940777 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2003:1940509 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2003:1940371 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2002:2995642 CHEMCATS, PD: January 17, 2002	
BC		Chemical Abstract AN: 2002:2977312 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2002:2647933 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2002:2272781 CHEMCATS, PD: July 9, 2002	
BC		Chemical Abstract AN: 2002:1467769 CHEMCATS, PD: January 17, 2002	
BC		Chemical Abstract AN: 2002:1464450 CHEMCATS, PD: January 17, 2002	

Examiner Signature	Brenda Coleman	Date Considered	May 24, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in performance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0691-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/743,852
		Filing Date	December 22, 2003
		First Named Inventor	Rocco Dean Gogliotti, et al.
		Art Unit	Not Yet Known 1624
		Examiner Name	Not Yet Known COLEMAN
Sheet	2	of	2
		Attorney Docket Number	PC 25547A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		Chemical Abstract AN: 2002:1461688 CHEMCATS, PD: January 17, 2002	
BC		Chemical Abstract AN: 2002:1460415 CHEMCATS, PD: January 17, 2002	
BC		Chemical Abstract AN: 2002:1458784 CHEMCATS, PD: January 17, 2002	
BC		Chemical Abstract AN: 2002:1455387 CHEMCATS, PD: January 17, 2002	

Examiner Signature	Rienda Coleman	Date Considered	May 24, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.